Jordan’s Q2 2026 GDP Expands 3.0%, Outperforming Regional Headwinds, International Forecasts
ENV-KUWAIT-SUSTAINABLITYKuwait strengthens environmental sustainability through strategic initiativesBy Zahra Al-Kadhmi
HLT-KUWAIT-SURGERYKuwait advances health sector with robotic, remote surgeryBy Mohammad Al-Moseb
Saudi Arabia’s Voluntary Carbon Market Fuels the Shift to a Low-Carbon
Moscow, Oct. 18 (Petra) — The National Medical Research Radiological
Centre of the Ministry of Health of the Russian Federation announced
on Sunday the successful completion of phases I and II of clinical
trials for a liver cancer treatment named “Hepatorin-mRNC,” targeting
primary tumors and liver metastases.
Chief Oncologist of the Russian Ministry of Health, Andrey Kaprin,
stated that the drug utilizes albumin microspheres loaded with a
radioactive isotope, enabling targeted radiation therapy delivered
directly to the tumor. He confirmed that both Phase I and Phase II
clinical studies have been completed.
//Petra// AF
